REVIEW

Ann K. Daly

Development of analytical technology in pharmacogenetic research

Abstract Methods used to determine phenotype and genotype for pharmacogenetic polymorphisms are discussed. Phenotyping is mainly applicable to polymorphisms affecting drug disposition rather than drug response and can involve either direct measurement of enzyme activity or administration of a probe drug followed by measurement of drug and/or metabolite levels. Genotyping is now more widely used than phenotyping and can be used to determine genotype for polymorphisms affecting either drug disposition (for example those in the cytochromes P450 or N-acetyltransferases) or drug response (for example those in drug receptors). Most genotyping for known polymorphisms involves use of the polymerase chain reaction and the wide variety of methods based on this technique that are now used for routine genotyping are discussed in detail. In addition, a range of methods that can be used to detect novel polymorphisms, thereby further increasing understanding of interindividual variability in drug disposition and response, is described.

Keywords Genotype · Phenotype · Polymerase chain reaction · Pharmacogenetics · Mutation detection

Introduction

A wide range of methods for the analysis of pharmacogenetic polymorphisms is now available. These can be divided into those concerned with phenotype determination, either by measurement of enzyme levels or monitoring levels of a metabolite in blood or urine, and genotyping methods, where DNA is analysed directly for the occurrence of a specific genetic polymorphism, usually following amplification of part of the gene of interest by PCR. Phenotypic analysis is mainly only applicable to metabolising enzymes whereas genotypic analysis can be applied to a wide range of genes encoding proteins of pharmacogenetic interest including enzymes, receptors and transporters. Genotyping is now the method of choice for most pharmacogenetic studies and the increasing availability of genome sequence data is likely to lead to an increased knowledge of pharmacogenetic polymorphisms known to result in functionally significant effects on drug disposition or responses. However, the important early discoveries in pharmacogenetics such as the N-acetyltransferase (NAT2) and CYP2D6 debrisoquine/sparteine polymorphisms (Evans et al. 1960; Mahgoub et al. 1977) were achieved by phenotypic analysis and there is still a need for effective phenotyping methods for some types of study. Specific examples of such studies include in vivo drug interaction studies on specific cytochrome P450 isoforms such as CYP2D6 and population studies on certain enzymes such as CYP1A2, CYP3A4 and CYP2E1 where there is some evidence for genetically-determined variability in enzyme levels but the molecular basis of this variation remains unclear. Also, in the case of some polymorphisms, phenotypic analysis may be considered to be more sensitive in identifying all individuals with a particular deficiency than genotyping where it is not usually possible to screen for certain rare or unknown polymorphisms. This is theoretically the case for the CYP2D6, CYP2C19 and thiopurine methyltransferase (TPMT) polymorphisms. However, in comparing assay sensitivity the fact that subject compliance and use of interfering drugs can decrease the accuracy of phenotypic analysis involving probe drug administration should also be considered. Direct enzyme assays such as that for TPMT levels in erythrocytes present fewer problems of this nature. Both types of phenotyping assays require a definition for the abnormal phenotype and occasionally it may be difficult to define phenotype if the measurement for an individual falls at the border of the normal and abnormal phenotype. With genotyping this problem will not arise.

A. K. Daly (✉)
Pharmacogenetics Group,
School of Clinical and Laboratory Sciences, Medical School,
University of Newcastle upon Tyne,
Framlington Place, Newcastle upon Tyne, NE2 4HH, UK
Tel.: +44-191-2227031
e-mail: a.k.daly@ncl.ac.uk

Phenotype determination

The most convenient approach to population phenotyping is to measure levels of enzyme activity or protein in an accessible tissue such as erythrocytes or leukocytes. Unfortunately, many enzymes of pharmacogenetic interest are not expressed at high levels in these cells. This is particularly so for most cytochrome P450 isoforms, which are mainly expressed at high levels only in the liver though there are now some reports of measurements in leukocytes using sensitive methods such as immunoblotting (Raucy et al. 1997). The validity of using levels of enzyme activity in leukocytes as a surrogate for levels in other tissues is however questionable (Hukkanen et al. 1997). Because of the limitations with the use of direct enzyme measurement in blood cells, phenotypic analysis involving administration of probe drugs is the most widely used method for phenotype determination at present. Table 1 summarises the main phenotyping methods, either involving direct enzyme assay or use of a probe drug, that have been used in population studies on interindividual variability in activity for a variety of xenobiotic metabolising enzymes and related proteins.

Methods using probe drugs

As summarised in Table 1, a range of probe drugs have been utilised for phenotyping studies, particularly for CYP2D6, CYP2C19, CYP2C9, CYP3A4 and NAT2. The subject of cytochrome P450 probe drugs has been reviewed in some detail (Streetman et al. 2000). As discussed by these authors, there are well-established and effective probe drugs available for CYP2D6 and, to a lesser extent, CYP2C9. Though mephenytoin is a widely-used and sensitive probe for CYP2C19, there are concerns about its safety and no completely satisfactory alternative is currently available. A large number of different probe drugs have been used in studies on CYP3A4 but, as discussed by Streetman et al. (2000), there are certain drawbacks to each and no ideal probe for this enzyme in population studies on interindividual variation in activity has yet emerged. There is still controversy about the extent of polymorphism in CYP3A4. An upstream polymorphism has been detected but its functional significance remains uncertain (Rebbeck et al. 1998; Westlind et al. 1999). A number of coding region polymorphisms are also known including one showing substrate-dependent effects on activity (Sata et al. 2000). The existence of substrate-dependent polymorphisms makes the interpretation of phenotyping data relating to CYP3A4

Table 1 Phenotyping methods for analysis of pharmacogenetic polymorphisms

Gene	Method	Type of sample	References
Cholinesterase	Enzyme inhibition	Plasma	(Whittaker et al. 1983)
COMT	Enzyme levels	Erythrocytes	(Weinshilboum and Raymond 1977)
CYP1A1	Induced enzyme activity	Lymphocytes	(Kouri et al. 1982)
CYP1A2	Caffeine as probe drug	Blood, Urine or Saliva	(Campbell et al. 1987); Fuhr and Rost 1994)
CYP2A6	Coumarin as probe drug	Urine	(Cholerton et al. 1992)
CYP2C9	Tolbutamide as probe drug	Urine	(Veronese et al. 1990)
CYP2C19	Mephenytoin as probe drug	Urine	(Wedlund et al. 1984)
CYP2C19	Omeprazole as probe drug	Urine	(Chang et al. 1995)
CYP2D6	Debrisoquine as probe drug	Urine	(Idle et al. 1979)
CYP2D6	Sparteine as probe drug	Urine	(Eichelbaum et al. 1979)
CYP2D6	Dextromethorphan as probe drug	Urine	(Jacqz-Aigrain et al. 1989)
CYP2D6	Metoprolol as probe drug	Urine	(Lennard 1985)
CYP2E1	Chlorzoxazone as probe drug	Blood	(Kim et al. 1995)
CYP2E1	Direct measurement	Lymphocytes	(Raucy et al. 1997)
CYP3A4	Midazolam as probe drug	Blood	(Thummel et al. 1994)
CYP3A4	6-hydroxycortisol	Urine	(Zhiri et al. 1986)
CYP3A4	Erythromycin breath test	Breath test	(Watkins et al. 1990)
FMO3	Trimethylamine levels	Urine	(Alwaiz et al. 1989)
GSTM1	Enzyme levels	Leucocytes	(Seidegard and Pero 1985)
GSTT1	Enzyme levels	Erythrocytes	(Hallier et al. 1993)
NAT1	4-aminobenzoate as probe drug	Urine	(Cribb et al. 1994)
NAT2	Caffeine as probe drug	Urine	(Grant et al. 1983)
Paraoxonase	Enzyme levels	Plasma	(Playfer et al. 1976)
Sulfotransferase	Enzyme levels	Platelet	(Price et al. 1988, 1989)
TPMT	Enzyme levels	Erythrocytes	(Weinshilboum and Sladek 1980)
P-glycoprotein	Digoxin clearance	Blood	(Greiner et al. 1999)

The methods described above have been used in population studies and are all based either on probe drug administration or direct measurement of enzyme activity in an accessible tissue. In the case of these and other enzymes, direct measurement of activity in clinical samples such as liver is also usually feasible

more difficult as does the fact that 10–20% of livers also express the homologous CYP3A5, which shows some differences in substrate specificity to CYP3A4 (Aoyama et al. 1989; Gillam et al. 1995). However, many phenotyping studies on CYP3A4 are concerned with determining the extent of induction or inhibition by new drugs and currently available phenotyping methods including the erythromycin breath test and use of midazolam are useful in such cases. Caffeine is a widely used probe for CYP1A2 activity but there is still uncertainty regarding the precise metabolic ratio that should be used and the functional significance of several upstream polymorphisms (Nakajima et al. 1999; Sachse et al. 1999; Sinues et al. 1999; Sachse et al. 2003).

In the case of non-P450 enzymes, NAT2 has been the most comprehensively studied by use of probe drugs. A wide variety of drugs have been used but caffeine is currently the most convenient probe (Grant et al. 1983). The homologous *NAT1* gene has also been shown to exhibit polymorphism at a low frequency using 4-aminobenzoic acid as probe drug (Cribb et al. 1994). Phenotype for the polymorphic flavin-linked monooxygenase FMO3 can be determined by analysis of levels of endogenous trimethylamine in urine (Alwaiz et al. 1989). In the case of UDP-glucuronosyltransferases (UGT), a number of probe drugs have been used in phenotyping studies. Some evidence for the existence of considerable interindividual variation in levels of activity has emerged from these studies but interpretation of the data is made difficult by the possibility that some of the probe drugs used may be substrates for more than one UGT isoform (Liu et al. 1995; Patel et al. 1995; Shimoda et al. 1995; Yue et al. 1997).

Up to the present, the majority of studies using probe drugs have been concerned with measurement of levels of xenobiotic metabolising enzymes only. However, interindividual variation in absorption, distribution and excretion is also clearly of importance to overall drug disposition. Levels of plasma digoxin in healthy volunteers were used as a measure of absorption and a correlation found between presence of a polymorphism in the P-glycoprotein (PGP) encoding *MDR1* gene, which is apparently linked to low levels of PGP expression and high plasma levels of the drug (Hoffmeyer et al. 2000). These findings have not been confirmed in all subsequent studies and the precise functional significance of several *MDR1* polymorphisms remains controversial (Kim 2002).

Direct measurement

Phenotyping by direct measurement of enzyme activity is a useful technique in the study of many pharmacogenetic polymorphisms affecting drug metabolism but as mentioned above there are problems with low or absent enzyme expression in accessible tissues. In the case of the cytochromes P450 enzyme levels are often measured in human liver microsomes but obtaining suitable liver samples presents some ethical and practical problems. In particular, the extent of interindividual variation in enzyme activity may be overestimated if all specimens used are not in good condition with uniform methods used for preparation of microsomes.

Use of blood cells presents fewer difficulties if the enzyme of interest is expressed at sufficient level for detection and the data obtained is genuinely representative of gene expression in other tissues as well. As summarised in Table 1, studies using erythrocytes or leukocytes have resulted in the detection of polymorphisms affecting a number of phase II enzymes including the glutathione *S*-transferases GSTM1 and GSTT1 (Seidegard and Pero 1985; Hallier et al. 1993), the methyltransferases TPMT (Weinshilboum and Sladek 1980) and catechol *O*-methyltransferase (COMT) (Weinshilboum and Raymond 1977) and the phenol sulfotransferases (Price et al. 1988, 1989). In addition, an apparent polymorphism affecting the extent of CYP1A1 induction by polycyclic aromatic hydrocarbons has been detected in cultured lymphocytes (Kouri et al. 1982).

Genotype determination

Sequence data now exists on a wide range of genes relevant to pharmacogenetics, many of which are known to show polymorphism. The molecular basis of most polymorphisms previously detected by phenotypic analysis is now known and it is now possible to use simple genotyping assays to predict phenotype accurately. In addition, it is also possible to detect new polymorphisms for which no previous phenotypic data existed by either directly scanning coding or regulatory sequences for polymorphisms or comparison of several independently sequenced cDNA or genomic clones. This is an increasingly important approach, which is being greatly facilitated by the availability of the Human Genome Project sequence data. In particular, it is now possible to obtain data on polymorphism in receptors and other drug targets on which phenotypic studies have been difficult in the past. Polymorphisms, including the most common type the single nucleotide polymorphism (SNP), occur at typical frequencies of 1 per 1,000 bp in the genome. However, even in coding sequences the majority will not be functionally significant. Once novel polymorphisms have been identified, the next step in their study is usually assessment of their functional significance. In the case of polymorphisms in a protein coding region, the most important consideration is whether they result in any alterations in the protein sequence. If a polymorphism results in a premature stop codon or frameshift, there is a high likelihood of functional significance and many amino acid substitutions will also affect function, particularly if they are non-conservative or occur in an area of the protein critical to structure or function. However, many novel polymorphisms are silent or result in conservative amino acid substitutions. There are reports of some silent polymorphisms altering RNA stability (Milland et al. 1996) but in general such polymorphisms are unlikely to be of functional significance though possibly of interest for linkage studies. Where an amino acid substitution has

occurred, direct assessment of its functional significance will require expression of the mutant protein for assessment of its biological properties. It may also be possible to assess functional significance by determining phenotype in individuals or isolated tissue samples positive for the variant genotype of interest.

It is more difficult to predict effects of polymorphisms occurring outside protein coding sequences but those in promoter regions may affect gene expression, those in introns can interfere with RNA splicing and those at the 3'-end of a gene may affect RNA stability. The most usual approach to studying functional significance of promoter region polymorphisms is to compare the effects of mutant and wild-type sequence fused to reporter gene constructs. Other approaches to the study of functional effects of polymorphisms in regulatory regions include comparison of transcript levels for the gene of interest between samples from individuals of different genotypes.

Screening for known polymorphisms

Background

Most genotyping assays currently used to screen for known pharmacogenetic polymorphisms involve use of the polymerase chain reaction (PCR) followed by a specific detection step. Other amplification methods such as the oligonucleotide ligation detection assay (OLA) are occasionally used. The type of amplification-based assay used can range from relatively simple but slow and low-throughput methods such as restriction fragment length polymorphism-PCR (RFLP-PCR) analysis, single strand conformational polymorphism (SSCP) analysis or allele-specific PCR analysis to more specialised higher-throughput detection methods such as microarrays and sequencing. The choice of method will be determined by a number of factors including equipment available in the laboratory and number of samples to be analysed now and in the future.

An important issue in pharmacogenetics is whether the genotyping method chosen for a particular gene results in the identification of all possible variant alleles with 100% detection of all individuals of a particular phenotype. This is problematic since even if DNA sequencing, which should identify all known polymorphisms is used as assay method, some individuals with a particular phenotype may have a previously unknown polymorphism present. It will seldom be possible to predict the precise effect of a new polymorphism on phenotype without further experimentation. Designing assay systems that will screen for all very rare polymorphisms also presents difficulty. Thus, in the case of polymorphic genes such as CYP2D6 or NAT2, most current genotyping approaches successfully identify only 95 to 99% of all individuals with the particular phenotype (Chen et al. 1996; Grant et al. 1997; Sachse et al. 1997; Leathart et al. 1998; Cascorbi and Roots 1999). Since as discussed above, there are also limitations to the accuracy of phenotyping methods, this is generally re-

garded as adequate for most purposes. Providing appropriate quality control measures are in place (see below), false positive results should not occur with genotyping assays.

There are a wide range of publications concerning successfully amplifying sequences by PCR and a wide range of reagents to make the process easier are now commercially available. However, there are a few general points that are particularly important when performing PCR on genes relevant to xenobiotic metabolism. For many of these genes, it is important to use the highest annealing temperatures compatible with satisfactory amplification of the required sequence with the chosen primers to ensure that other sequences with homology to the gene of interest such as pseudogenes are not also amplified. Other factors important in successful PCR include choice of heat stable DNA polymerase and whether additional refinements such as "hot start" or long PCR conditions are required. Heat stable DNA polymerases from different suppliers vary in their ability to successfully amplify using different primer sets and it is advisable that enzyme from the same supplier should be used consistently for particular reactions.

PCR-RFLP

This method involves digestion of a PCR product with a restriction enzyme that distinguishes between the wild-type and mutant sequence. The method is most valuable when the polymorphism introduces a direct alteration in a restriction site so that a restriction site is lost or created, but even if there is no change in restriction enzyme sites as a result of a polymorphism, it may also be possible to engineer one or more base changes using a mismatched primer so that a new site seen only for either the mutant or wild-type sequence is created. Restriction patterns are analysed by gel electrophoresis on either agarose gels when the difference in fragment sizes is greater than approximately 40 bp or polyacrylamide gels where the difference is smaller such as in the case of an engineered restriction site. For genes where more than one polymorphism can occur such as CYP2D6 or NAT2, it may be possible to amplify a relatively large gene fragment and digest with several restriction enzymes, either together or in parallel reactions (Bell et al. 1993; Daly et al. 1996). With respect to restriction enzyme digestion, it is important to have an internal control for the enzyme activity in each tube to check that complete digestion has occurred. This can be an additional restriction site in the PCR product that is not subject to polymorphism or an additional PCR product with a site for the enzyme that will yield products of different non-interfering size. Careful observation of relative band intensities prior to genotype assignment is also important in avoiding misclassification due to partial digestion.

Allele-specific and sequence specific PCR

Allele and sequence specific PCR involves the specific amplification of individual alleles followed by a single detection step usually gel electrophoresis. Two alleles can be amplified in the same tube providing allele-specific primers that give products of different sizes are included. In some cases where large deletions or insertions occur, the same primers can be used for both alleles with the individual alleles distinguished purely on the basis of electrophoretic mobility. It is also possible to carry out two PCR separate reactions in parallel, one specific for the wild-type allele and one for the variant allele. With allele-specific PCR reactions, it is important that amplification of a non-polymorphic sequence of a different size from a control gene be carried out in the same tube to ensure that lack of product is not simply due to failure of the amplification reaction. Although allele-specific PCR and sequence-specific PCR often work well and involve fewer steps than RFLP-based methods or SSCP analysis, the specificity of the PCR reactions, which is vital to the successful use of methods involving the use of allele-specific primers, may be affected by variations in the laboratory temperature, which presumably results in slight changes in the temperature of the annealing step in the thermocycler.

Some new techniques that overcome the difficulties of achieving specificity and reproducibility in allele-specific PCR have been developed. The dynamic allele-specific hybridisation (DASH technique) (Howell et al. 1999) involves initial amplification of a biotin-labelled PCR product spanning the polymorphic site of interest and immobilisation of one strand to a streptavidin-coated well followed by hybridisation to allele specific probes at the site of the polymorphism. The melting behaviour of the double stranded DNA is then followed by use of a fluorescent dye that binds to double stranded DNA only with decreased fluorescence indicating denaturation. Any mismatch will be associated with denaturation at a lower temperature.

SSCP analysis

Single strand conformational polymorphism analysis is currently a widely used polymorphism scanning technique because of its simplicity and relatively high sensitivity (Orita et al. 1989). The basis of the method is that if a double stranded PCR product is denatured and applied to non-denaturing polyacrylamide electrophoresis gel, both strands will form intrastrand secondary structure whose electrophoretic mobility will differ in a sequence dependent manner. Where a mobility shift is detected, the sample is sequenced to determine the sequence change and its location. The precise sensitivity of SSCP analysis in mutation detection remains controversial with estimates of approximately 80% commonly quoted for a 300 bp PCR product when the analysis is done under at least two different electrophoretic conditions varying by temperature and/or glycerol content of the gel (Ravnik-Glavac et al. 1994). The original description of the technique involved using ^{32}P-labelled primers and sequencing gel equipment but methods without radiolabelling and using smaller polyacrylamide gels have also been developed (Hongyo et al. 1993). While problems with sensitivity may limit the usefulness of SSCP for mutation scanning, it is frequently a useful technique for routine screening for polymorphisms and generally will give consistent results providing samples are denatured adequately and consistent electrophoresis conditions especially with respect to temperature are used. It is particularly important for accurate genotype designation that positive controls of known genotype previously checked by DNA sequencing should be included on each gel when using SSCP analysis for routine detection of polymorphisms.

Other methods

There are a variety of newer methods available for routine genotyping including use of high throughput systems involving microarrays and MALDI-TOF. Genotyping by minisequencing, which involves primer extension of a PCR product using dideoxynucleotides, is a less specialised technique that can be multiplexed (Syvanen 1999). Adaptation to a microarray-based format to achieve higher throughput is also possible. Pyrosequencing is a specialised form of minisequencing that uses iterative nucleotide dispensation with detection of incorporation by real-time measurement of pyrophosphate production (Alderborn et al. 2000). Pyrophosphate is detected in a series of enzymatic reactions that result in light generation. The ability to multiplex and the availability of automated equipment allows high sample throughput.

Quality control issues

In addition to the normal controls needed in carrying out any amplification by PCR, it is important that control DNA samples of known genotype are analysed in parallel with test samples regardless of the method being used for genotyping. In the case of rare polymorphisms, obtaining adequate amounts of DNA may be difficult. Use of cloned DNA rather than human genomic DNA as a control is an alternative. As discussed previously, there are particular problems concerning specificity that may be encountered when amplifying P450 genes and other members of multigene families because of the existence of highly homologous genes. These problems can be dealt with by careful design of primers, use of high annealing temperatures and checking the sequence of PCR products when setting up the assay initially. If problems persist, use of nested PCR may enable greater specificity to be achieved. Quality control issues in relation to NAT2 genotyping have been considered in detail (Cascorbi and Roots 1999) but many of the points discussed by these authors are also relevant to the analysis of other polymorphisms.

Identification and characterisation of novel polymorphisms

In spite of the large number of pharmacogenetic polymorphisms now detected and characterised, it is clear that many more exist. Providing genomic sequence information on the gene of interest is available, there are a number of different approaches to detecting novel polymorphisms (for review see Cotton 1997). DNA sequencing is probably the most accurate though if double stranded PCR products are sequenced there is a risk of missing some heterozygosity, even if traces from automated sequencing are scanned visually. In general, sequencing is a particularly useful method for mutation detection when a small number of samples of a known phenotype are available. Random population scanning of up to 100 DNA samples from particular ethnic groups for polymorphisms in genes of interest is also being increasingly performed (Cargill et al. 1999). Techniques such as SSCP and denaturing gradient gel electrophoresis (DGGE) analysis can be used for such studies but denaturing HPLC (DHPLC), which involves detection of heteroduplexes in PCR products on the basis of a mobility shift on a ion paired reversed phase liquid chromatography column, is being increasingly used. Although the equipment is relatively expensive initially, the technique offers the advantages of speed, the ability to automate and low running costs. It has a sensitivity for polymorphism detection in excess of 90% (Xiao and Oefner 2001). DHPLC is primarily a method for detecting heteroduplexes so samples homozygous for a mutation can be missed unless wild-type PCR product is added to form artificial heteroduplexes.

Conclusion

A variety of approaches to the analysis of both phenotype and genotype have been discussed. At present, the relationship between phenotype and genotype is well understood for a few genes concerned with drug disposition but there is still a need for further studies on aspects such as ethnic variation in patterns of polymorphisms and increased understanding on the extent of polymorphism in the full range of genes encoding proteins relevant to drug disposition. In the case of drug targets, the amount of information on polymorphisms is more limited and there is a need to understand more about both the extent of polymorphism and the phenotypic effects of polymorphisms for the possibility of individualisation of drug treatment to become a reality. This greater understanding is likely to be facilitated both by the availability of sequence information from the Human Genome Project and by the development of improved methods for polymorphism detection.

References

Alderborn A, Kristofferson A, Hammerling U (2000) Determination of single-nucleotide polymorphisms by real-time pyrophosphate sequencing. Genome Res 10:1249–1258

Alwaiz M, Ayesh R, Mitchell SC, Idle JR, Smith RL (1989) Trimethylaminuria – the detection of carriers using a trimethylamine load test. J Inherit Metab Dis 12:80–85

Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin HV, Gonzalez FJ (1989) Cytochrome P450 hPCN3, a novel cytochrome P450 IIA gene product that is differentially expressed in adult human liver. J Biol Chem 264:10388–10395

Bell DA, Taylor JA, Butler MA, Stephens EA, Wiest J, Brubaker LH, Kadlubar FF, Lucier GW (1993) Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 14:1689–1694

Campbell ME, Spielberg SP, Kalow W (1987) A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 42:157–165

Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES (1999) Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 22:231–238

Cascorbi I, Roots I (1999) Pitfalls in N-acetyltransferase 2 genotyping. Pharmacogenetics 9:123–127

Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L (1995) Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5:358–363

Chen SQ, Chou WH, Blouin RA, Mao ZP, Humphries LL, Meek C, Neill JR, Martin WL, Hays LR, Wedlund PJ (1996) The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 60:522–534

Cholerton S, Idle ME, Vas A, Gonzalez FJ, Idle JR (1992) Comparison of a novel thin-layer chromatographic-flourescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine. J Chromatogr 575:325–330

Cotton RGH (1997) Slowly but surely towards better scanning for mutations. Trends Genet 13:43–46

Cribb AE, Isbrucker R, Levatte T, Tsui B, Gillespie CT, Renton KW (1994) Acetylator phenotyping: the urinary caffeine metabolite ratio in slow acetylators correlates with a marker of systemic NAT1 activity. Pharmacogenetics 4:166–170

Daly AK, Steen VM, Fairbrother KS, Idle JR (1996) *CYP2D6* multiallelism. Meth Enzymol 272:199–210

Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 17:153–155

Evans DAP, Storey PB, McKusick VA (1960) Genetic control of isoniazid metabolism in man. Br Med J 2:485–491

Fuhr U, Rost K (1994) Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and saliva. Pharmacogenetics 4:109–116

Gillam EMJ, Guo Z, Ueng Y-F, Yamazaki H, Cock I, Reilly PEB, Hooper WD, Guengerich FP (1995) Expression of cytochrome P450 3A5 in *Escherichia coli*: effects of 5'modification, purification, reconstitution conditions, and catalytic activities. Arch Biochem Biophys 317:374–384

Grant DM, Tang BK, Kalow W (1983) Polymorphic N-acetylation of a caffeine metabolite. Clin Pharmacol Ther 33:355–359

Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, Yu VL, Grewal R (1997) Human acetyltransferase polymorphisms. Mutat Res 376:61–70

Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, VonRichter O, Zundler J, Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147–153

Hallier E, Langhof T, Dannappel D, Leutbecher M, Schroder K, Goergens HW, Muller A, Bolt HM (1993) Polymorphism of glutathione conjugation of methyl-bromide, ethylene-oxide and dichloromethane in human blood – influence on the induction of sister chromatid exchanges (SCE) in lymphocytes. Arch Toxicol 67:173–178

Hoffmeyer S, Burk O, vonRichter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473–3478

Hongyo T, Buzard GS, Calvert RJ, Weghorst CM (1993) Cold SSCP – a simple, rapid and nonradioactive method for optimized single-strand conformation polymorphism analyses. Nucleic Acid Res 21:3637–3642

Howell WM, Jobs M, Gyllensten U, Brookes AJ (1999) Dynamic allele-specific hybridization – a new method for scoring single nucleotide polymorphisms. Nat Biotech 17:87–88

Hukkanen J, Hakkola J, Anttila S, Piipari R, Karjalainen A, Pelkonen O, Raunio H (1997) Detection of mRNA encoding xenobiotic-metabolizing cytochrome P450 s in human bronchoalveolar macrophages and peripheral blood lymphocytes. Mol Carcinog 20:224–230

Idle JR, Mahgoub A, Angelo MM, Dring LG, Lancaster R, Smith RL (1979) The metabolism of [14C] debrisoquine in man. Br J Clin Pharmacol 7:257–266

Jacqz-Aigrain E, Menard Y, Popon M, Mathieu H (1989) Dextromethorphan phenotypes determined by high-performance liquid chromatography and fluorescence detection. J Chromatogr 495:361–363

Kim RB (2002) MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. Pharmacogenetics 12:425–427

Kim RB, O'Shea D, Wilkinson GR (1995) Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to *CYP2E1* genetic polymorphisms. Clin Pharmacol Ther 57:645–655

Kouri RE, McKinney CE, Slomiany DJ, Snodgrass DR, Wray NP, McLemore TL (1982) Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analysed in cryopreserved lymphocytes. Cancer Res 42:5030–5037

Leathart JBS, London SJ, Adams JD, Idle JR, Daly AK (1998) CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians. Pharmacogenetics 8:529–542

Lennard MS (1985) Quantitative-analysis of metoprolol and 3 of its metabolites in urine and liver-microsomes by high-performance liquid-chromatography. J Chromatogr 342:199–205

Liu ZR, Mortimer O, Smith CAD, Wolf CR, Rane A (1995) Evidence for a role of cytochrome P450 2D6 and 3A4 in ethylmorphine metabolism. Br J Clin Pharmacol 39:77–80

Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet ii: 584–586

Milland J, Christiansen D, Thorley BR, McKenzie IFC, Loveland BE (1996) Translation is enhanced after silent nucleotide substitutions in A+T-rich sequences of the coding region of CD46 cDNA. Eur J Biochem 238:221–230

Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T (1999) Genetic polymorphism in the 5 '-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 125:803–808

Orita M, Suzuki Y, Sekiya T, Hayashi K (1989) Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5:874–879

Patel M, Tang BK, Grant DM, Kalow W (1995) Interindividual variability in the glucuronidation of (S)-oxazepam contrasted with that of (R)-oxazepam. Pharmacogenetics 5:287–297

Playfer JR, Eze LC, Bullen MF, Evans DAP (1976) Genetic polymorphism and inter-ethnic variability of plasma paraoxonase activity. J Med Genet 13:337–342

Price RA, Cox NJ, Spielman RS, Van Loon JA, Maidak BL, Weinshilboum RM (1988) Inheritance of human platelet thermolabile phenol sulphotransferase (TLPST) activity. Genet Epidemiol 5:1–15

Price RA, Spielman RS, Lucena AL, Van Loon JA, Maidak BL, Weinshilboum RM (1989) Genetic polymorphism for human platelet thermostable phenol sulphotransferase (TSPST) activity. Genetics 122:905–914

Raucy JL, Schultz ED, Wester MR, Arora S, Johnston DE, Omdahl JL, Carpenter SP (1997) Human lymphocyte cytochrome P450 2E1, a putative marker for alcohol-mediated changes in hepatic chlorzoxazone activity. Drug Metab Dispos 25:1429–1435

Ravnik-Glavac M, Glavac D, Dean M (1994) Sensitivity of single-strand conformation polymorphism and heteroduplex method for mutation detection in the cystic-fibrosis gene. Hum Mol Genet 3:801–807

Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 90: 1225–1229

Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284–295

Sachse C, Brochmoller J, Bauer S, Roots I (1999) Functional significance of a C→A polymorphism in intron I of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445–449

Sachse C, Bhambra U, Smith G, Lightfoot TJ, Barrett JH, Scollay J, Garner RC, Boobis AR, Wolf CR, Gooderham NJ (2003) Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol 55:68–76

Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL, Gonzalez FJ (2000) CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 67:48–56

Seidegard J, Pero RW (1985) The hereditary transmission of high glutathione transferase-activity towards trans-stilbene oxide in human mononuclear leukocytes. Hum Genet 69:66–68

Shimoda K, Noguchi T, Ozeki Y, Morita S, Shibasaki M, Someya T, Takahashi S (1995) Metabolism of clomipramine in a Japanese psychiatric population – hydroxylation, desmethylation, and glucuronidation. Neuropsychopharmacology 12:323–333

Sinues B, Saenz MA, Lanuza J, Bernal ML, Fanlo A, Juste JL, Mayayo E (1999) Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow. Cancer Epidemiol Biomarkers Prev 8:159–166

Streetman DS, Bertino JS, Nafziger AN (2000) Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo phenotyping probes. Pharmacogenetics 10:187–216

Syvanen AC (1999) From gels to chips: "minisequencing" primer extension for analysis of point mutations and single nucleotide polymorphisms. Hum Mutat 13:1–10

Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, McVicar JP, Barr DM, Perkins JD, Carithers RL (1994) Use of midazolam as a human cytochrome-P450 3a probe. I. In-vitro in-vivo correlation in liver-transplant patients. J Pharmacol Exp Ther 271:549–556

Veronese ME, Miners JO, Randles D, Gregov D, Birkett DJ (1990) Validation of the tolbutamide metabolic ratio for population screening with the use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther 47:403–411

Watkins PB, Hamilton TA, Annesley TM, Ellis CN, Kolars JC, Voorhees JJ (1990) The erythromycin breath test as a predictor of cyclosporine blood-levels. Clin Pharmacol Ther 48:120–129

Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA (1984) Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 36:773–780

Weinshilboum RM, Raymond FA (1977) Inheritance of low erythrocyte catechol-O-methyltransferase activity in man. Am J Hum Genet 29:125–135

Weinshilboum R, Sladek SL (1980) Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32:651–662

Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman Sundberg M (1999) Interindividual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 5'-upstream regulatory region. Biochem Biophys Res Comm 259:201–205

Whittaker M, Britten JJ, Dawson PJG (1983) Comparison of a commercially available assay system with two reference methods for the determination of cholinesterase variants. Clin Chem 29:1746–1751

Xiao W, Oefner PJ (2001) Denaturing high-performance liquid chromatography: a review. Hum Mutat 17:439–474

Yue QY, Iselius L, Sawe J (1997) Indices and graphical approaches for the detection of interindividual and interethnic variations in codeine metabolism. Br J Clin Pharmacol 44:239–244

Zhiri A, Mayer HA, Michaux V, Wellmanbednawska M, Siest G (1986) 6-Beta-hydroxycortisol in serum and urine as determined by enzyme-immunoassay on microtitre plates. Clin Chem 32:2094–2097